Conatus Pharmaceuticals Inc. (CNAT)

[biotech2010]

Roth Capital raised their price target from $4 to $12 today:

Conatus, Novartis analyst commentary at Roth Capital Conatus price target raised to $12 from $4 at Roth Capital. Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.

Read more at:
https://thefly.com/landingPageNews.php?id=2537393

What's more interesting than the increased target is their acknowledgment that there is 'clarity' on the NVS deal (meaning NVS will exercise their option), they can't make that kind of statement after discussions with management unless it's truly a 'done deal'